Teva Pharm to market medical cannabis inhaler in Israel
Israel's Teva Pharmaceuticals has partnered with Tel Aviv-based Syqe Medical to market in Israel medical cannabis for pain management that is administered with an inhaler.
The companies said in a statement that this is the first time the medical cannabis sector has complied with pharmaceutical standards for inhalation, which is the most efficient means for administering the plant.
Teva, the world's largest generic drug maker, will be the exclusive marketer and distributor in Israel of the inhaler developed by Syqe Medical. It will be available for home use pending approvals from the country's Ministry of Health.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd